Results 1 to 10 of about 307,534 (356)

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

Haematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong   +4 more
doaj   +1 more source

Up-regulation of SNHG5 Expression Level in Patients with Chronic Myeloid Leukemia Compared with Normal Individuals [PDF]

مجله دانشکده پزشکی اصفهان, 2022
Background: Chronic myeloid leukemia is a type of myeloproliferative malignancy that is associated with translocation between chromosomes 9 and 22 and accounts for approximately 15% of all leukemia.
Zahra Shahpouri-Arani, Mohamad Reza Hajari, Javad Mohammadi-Asl, Najmaldin Saki   +3 more
doaj   +1 more source

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report

Онкогематология, 2022
Chronic myeloid leukemia is a ph-positive myeloproliferative disease, which is usually manifested by hyperleukocytosis and massive splenomegaly. Chronic myeloid leukemia is rare in childhood and adolescence, it accounts for 2 to 3 % of all leukemias ...
T. Yu. Pavlova, T. T. Valiev
doaj   +1 more source

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Leukemia, 2021
In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death ...
H. Kantarjian, T. Hughes, R. Larson, Dong-Wook Kim, S. Issaragrisil, P. le Coutre, G. Étienne, C. Boquimpani, R. Pasquini, R. Clark, V. Dubruille, I. Flinn, S. Kyrcz‐Krzemień, E. Mędraś, M. Zanichelli, I. Bendit, S. Cacciatore, Ksenia Titorenko, P. Aimone, G. Saglio, A. Hochhaus   +20 more
semanticscholar   +1 more source

T LYMPHOCYTE SUBSETS STUDIED IN A PATIENT WITH TWO ASSOCIATED HEMATOLOGIC NEOPLASIAS – CHRONIC LYMPHOCYTIC LEUKEMIA B AND CHRONIC MYELOID LEUKEMIA [PDF]

Romanian Journal of Medical Practice, 2019
Quantification of various cellular subpopulations facilitates the monitoring of hematological diseases, including chronic lymphocytic leukemia. Variations in the proportions of regulatory T cells in peripheral blood have been described in patients with
Georgiana Ene, Ana Maria Vlădăreanu, Horia Bumbea, Ion Dumitru   +3 more
doaj   +1 more source

Blast crisis in chronic myeloid leukemia: An immunophenotypic analysis

International Journal of Science Annals, 2022
Background and Aim of Study: There are two different phases of untreated chronic myeloid leukemia – chronic phase, and blast crisis – according to the World Health Organization classification of Hematolymphoid tumors.
Singh Akanksha, Singh Anurag , Kanaujia Sweta , Kushwaha Rashmi , Singh Uma Shankar   +4 more
doaj   +1 more source

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Leukemia, 2020
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus, M. Baccarani, R. Silver, C. Schiffer, J. Apperley, F. Cervantes, R. Clark, J. Cortes, M. Deininger, F. Guilhot, H. Hjorth-Hansen, T. Hughes, J. Janssen, H. Kantarjian, Dong-Kee Kim, R. Larson, J. Lipton, F. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, J. Radich, D. Réa, J. Richter, G. Rosti, P. Rousselot, G. Saglio, Susanne Saussele, S. Soverini, J. Steegmann, A. Turkina, A. Zaritskey, Ruediger Hehlmann   +33 more
semanticscholar   +1 more source

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

Leukemia, 2021
The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors (TKIs).
Y. Hsieh, K. Kirschner, M. Copland
semanticscholar   +1 more source

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

Cells, 2021
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after ...
Valentina R Minciacchi, Rahul Kumar, D. Krause   +2 more
semanticscholar   +1 more source

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia [PDF]

Anais Brasileiros de Dermatologia, 2017
: Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites.
Erica Rodrigues de Araujo Vasconcelos, Alexander Richard Bauk, Mayra Carrijo Rochael   +2 more
doaj   +1 more source